Prostate only radiotherapy using external beam radiotherapy: A clinician’s perspective
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeong Won | - |
dc.contributor.author | Joo, Chung Mi | - |
dc.date.accessioned | 2023-08-16T07:39:49Z | - |
dc.date.available | 2023-08-16T07:39:49Z | - |
dc.date.created | 2023-07-21 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 2307-8960 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/189060 | - |
dc.description.abstract | Prostate-only radiotherapy (PORT) is widely used as the definitive treatment for localized prostate cancer. Prostate cancer has an alpha/beta ratio; therefore, radiotherapy (RT) with a large fraction size is biologically effective for tumor control. The current external beam RT technique for PORT has been improved from three-dimensional conformal RT to intensity-modulated, stereotactic body, and image-guided RTs. These methods are associated with reduced radiation exposure to normal tissues, decreasing urinary and bowel toxicity. Several trials have shown improved local control with dose escalation through the aforementioned methods, and the efficacy and safety of intensity-modulated and stereotactic body RTs have been proven. However, the management of RT in patients with prostate cancer has not been fully elucidated. As a clinician, there are several concerns regarding the RT volume and dose considering the patient's age and comorbidities. Therefore, this review aimed to discuss the radiobiological basis and external beam technical advancements in PORT for localized prostate cancer from a clinician's perspective. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.title | Prostate only radiotherapy using external beam radiotherapy: A clinician’s perspective | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Joo, Chung Mi | - |
dc.identifier.doi | 10.12998/wjcc.v10.i29.10428 | - |
dc.identifier.scopusid | 2-s2.0-85139333054 | - |
dc.identifier.wosid | 000891904600004 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF CLINICAL CASES, v.10, no.29, pp.10428 - 10434 | - |
dc.relation.isPartOf | WORLD JOURNAL OF CLINICAL CASES | - |
dc.citation.title | WORLD JOURNAL OF CLINICAL CASES | - |
dc.citation.volume | 10 | - |
dc.citation.number | 29 | - |
dc.citation.startPage | 10428 | - |
dc.citation.endPage | 10434 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기 학술지(Review) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | INTENSITY-MODULATED RADIOTHERAPY | - |
dc.subject.keywordPlus | STEREOTACTIC BODY RADIOTHERAPY | - |
dc.subject.keywordPlus | CONFORMAL RADIATION-THERAPY | - |
dc.subject.keywordPlus | PELVIC LYMPH-NODES | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | HIGH-RISK | - |
dc.subject.keywordPlus | CONVENTIONAL RADIOTHERAPY | - |
dc.subject.keywordPlus | ANDROGEN SUPPRESSION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Prostate cancer | - |
dc.subject.keywordAuthor | Radiotherapy | - |
dc.subject.keywordAuthor | Radiation dose | - |
dc.subject.keywordAuthor | Radiation technique | - |
dc.subject.keywordAuthor | Radiation volume | - |
dc.identifier.url | https://www.wjgnet.com/2307-8960/full/v10/i29/10428.htm | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.